title: HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions.
abstract: In the vaccine strategy against HIV, bacillus Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis, is considered to be one of potential vectors for mucosal delivery of vaccine Ag. We analyzed the induction of the Ag-specific Ab response by nasal immunization with recombinant BCG vector-based vaccine (rBCG-V3J1) that can secrete the V3 principal neutralizing epitope of HIV. Mice were nasally immunized with rBCG-V3J1 (10 microg) three times at weekly intervals. Four weeks after the initial immunization, high titers of V3J1-specific IgG Abs were seen in serum. These high levels of HIV-specific serum IgG responses were maintained for >12 mo following nasal immunization without any booster immunization. V3J1-specific IgG-producing cells were detected in mononuclear cells isolated from spleen, nasal cavity, and salivary gland of the nasally vaccinated mice. Nasal rBCG-V3J1 also induced high levels of prolonged HIV-specific serum IgG responses in Th1 (IFN-gamma(-/-))- or Th2 (IL-4(-/-))-immunodeficient mice. Further, IgG3 was highest among V3 peptide-specific IgG subclass Ab responses in these immunodeficient mice as well as in wild-type mice. In addition, this Ag-specific serum IgG Abs induced by nasal immunization with rBCG-V3J1 possessed the ability to neutralize clinical isolate of HIV in vitro. These results suggested that the nasal rBCG-V3J1 system might be used as a therapeutic vaccine in addition to a prophylaxis vaccine for the control of AIDS.
authors.affiliation: Department of Mucosal Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Hiroi
authors.forename: H
authors.initials: H
authors.lastname: Goto
authors.forename: K
authors.initials: K
authors.lastname: Someya
authors.forename: M
authors.initials: M
authors.lastname: Yanagita
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: N
authors.initials: N
authors.lastname: Yamanaka
authors.forename: H
authors.initials: H
authors.lastname: Kiyono
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D000818:Animals; D001500:BCG Vaccine; D002478:Cells, Cultured; D015483:HIV Antibodies / Q000096:biosynthesis*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D016867:Immunocompromised Host; D007371:Interferon-gamma / Q000096:biosynthesis / Q000235:genetics; D015847:Interleukin-4 / Q000096:biosynthesis / Q000235:genetics; D007700:Kinetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009297:Nasal Mucosa; D010455:Peptides / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D001500:BCG Vaccine; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D010455:Peptides; D011994:Recombinant Proteins; D015847:Interleukin-4; D007371:Interferon-gamma